Nicotinell Freshmint (Nicotine Polacrilex)

Nicotine Polacrilex, the active ingredient in Nicotinell Freshmint, is a nicotine replacement therapy presented as a buccal formulation for buccal use. It is intended to help adults who smoke reduce withdrawal symptoms and cravings associated with quitting.\n\nGNH India supplies Nicotinell Freshmint as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide.

Nicotinell Freshmint is a nicotine replacement product used in the management of tobacco dependence.\n\nSmoking cessation: assists adult smokers in reducing cravings and withdrawal symptoms during quit attempts.\nNicotine addiction: provides controlled nicotine delivery to support gradual reduction of nicotine intake.\nTobacco dependence: helps transition from combustible cigarettes to a non‑smoking state under medical guidance.

Nicotinell Freshmint may cause a range of adverse reactions, most of which are mild and transient.\n\nCommon Side Effects:\n- Mouth irritation or soreness\n- Throat irritation\n- Nausea or upset stomach\n- Hiccups\n- Headache\n- Dyspepsia\n\nSerious or Rare Side Effects:\n- Allergic reaction (rash, swelling, difficulty breathing)\n- Severe mouth ulceration\n- Chest pain or palpitations\n- Arrhythmia\n- Persistent dizziness\n- Unexplained weight loss

Before using Nicotinell Freshmint, consider the following safety measures.\n\nCardiovascular assessment: evaluate for recent myocardial infarction or unstable angina.\nConcurrent nicotine products: avoid using other nicotine replacement therapies simultaneously.\nPregnancy and lactation: discuss potential risks with a healthcare professional.\nMedication review: inform the prescriber of all current medicines to assess interaction risk.\nStore at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Nicotinell Freshmint can interact with several drug classes; monitoring is advised.\n\nMajor Interactions (Avoid):\n- Monoamine oxidase inhibitors (MAOIs): may increase risk of hypertensive crisis.\n- Other nicotine replacement products: risk of nicotine overdose.\n\nModerate Interactions (Monitor Closely):\n- CYP2A6 inhibitors (e.g., cimetidine): may raise nicotine plasma levels.\n- Antidepressants (SSRIs, SNRIs): monitor for mood changes.\n- Antihypertensive agents: nicotine may diminish blood pressure‑lowering effects.